AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Ondine Biomedical Launches £8.5 Million Fundraising Effort for U.S. Phase 3 Clinical Trial
November 01, 2024 06:22 PM AEDT| By Team Kalkine MediaHighlights,Fundraising targets at least £8.5 million to fund a U.S. Phase 3 clinical trial for Ondine’s nasal photodisinfection technology.,A 36% increase in issued share capital is anticipated, with New Common Shares priced at 8.5 pence each.,Additi...
Smith+Nephew Q3 2024 Trading Update: Revenue Growth Moderates Amid China Headwinds, Positive 2025 Outlook
November 01, 2024 04:58 AM AEDT| By Team Kalkine MediaHighlights,Q3 revenue rose 4% YoY to $1,412 million, with strong growth outside China.,Orthopaedics, Sports Medicine, and Advanced Wound Management segments all showed gains.,2024 full-year revenue growth outlook revised to 4.5% due to China headwind...
Avacta Therapeutics Showcases Next Generation of pre|CISION® Medicines at R&D Spotlight Event
October 30, 2024 09:26 PM AEDT| By Team Kalkine MediaHighlights,Avacta Therapeutics hosted a live R&D Spotlight event in London, focusing on its next-generation peptide drug conjugates (PDC) aimed at targeted tumor treatment.,The company presented details about its innovative pre|CISION® candidates and...
GSK Adjusts Vaccine Sales Forecast as Q3 Holds Steady, Analysts See Potential
October 30, 2024 09:23 PM AEDT| By Team Kalkine MediaHighlights:,Vaccine Sales Fall Short:,Arexvy and Shingrix sales missed forecasts, leading to a second downgrade in GSK’s vaccine segment.,Overall Growth Maintained:,Revenues rose by 2% to £8 billion, with core EPS up 5% at 49.7p, driven by specialty...
GSK Maintains Positive Trajectory for 2024 Amid R&D Advances
October 30, 2024 09:12 PM AEDT| By Team Kalkine MediaHighlights,GSK's Q3 2024 sales reached £8.0 billion, reflecting a 2% decline at actual exchange rates (AER) but a 2% increase at constant exchange rates (CER).,Specialty Medicines showed robust growth, with sales up 19%, counterbalancing a significan...
Eli Lilly Shares Fall as Company Lowers Year-End Guidance After Q3 Revenue Miss
October 30, 2024 09:00 PM AEDT| By Team Kalkine MediaHighlights:,Lowered Annual Guidance:,Eli Lilly reduced its earnings forecast to $13.02–$13.52 per share, down from $16.10–$16.60.,Zepbound,Sales Miss Estimates:,Q3 sales of weight-loss drug,Zepbound,came in at,$1.26 billion,, falling short of the pro...
A decline in full year 2024 earnings is noted by Bioventix
October 30, 2024 08:45 PM AEDT| By Team Kalkine MediaHighlights,Bioventix reported a 6.2% increase in revenue for FY 2024, totaling £13.6 million, despite missing analyst estimates.,Net income decreased by 3.3%, resulting in an earnings per share (EPS) of £1.55, down from £1.61 in FY 2023.,The company’...
GSK sees a rise in quarterly sales, and Next enhances its full-year guidance
October 30, 2024 07:45 PM AEDT| By Team Kalkine MediaHighlights,GSK reported a 2% increase in constant exchange rate sales to £8 billion, driven by growth in specialty medicines despite a decline in vaccine sales.,Next raised its guidance for both fourth-quarter and full-year performance following a 7....
Hemogenyx Pharmaceuticals PLC outlines the schedule for its Phase I clinical trial
October 30, 2024 06:53 PM AEDT| By Team Kalkine MediaHighlights,Hemogenyx Pharmaceuticals plc has announced the schedule for launching its Phase I clinical trial for HEMO-CAR-T (HG-CT-1), targeting relapsed/refractory acute myeloid leukemia (AML) in adults.,Institutional Review Board (IRB) approval for...
Strong Q3 Results Boost Shield Therapeutics’ Financial Health Ahead of 2025
October 29, 2024 10:39 PM AEDT| By Team Kalkine MediaHighlights:,Shield Therapeutics (LSE:STX) reports robust Q3 revenue, driven by increased demand for Accrufer.,The company secures additional financing and targets positive cash flow by the end of 2025.,A potential $10 million equity investment from A...
Olympus Hit by Leadership Crisis as CEO Steps Down Amid Drug Scandal
October 28, 2024 07:21 PM AEDT| By Team Kalkine MediaHighlights:,Olympus CEO Stefan Kaufmann resigned after an internal probe into allegations of illegal drug purchases.,Kaufmann, the second non-Japanese CEO of the company, served since April 2023.,Chairman Yasuo Takeuchi will act as interim CEO while...
Three UK Stocks Highlighted for Possible Undervaluation of Up to 40.3%
October 24, 2024 07:57 PM AEDT| By Team Kalkine MediaHighlights,Market Downturn,: The UK stock market, including the FTSE 100 and FTSE 250, has faced recent declines influenced by weak trade data from China, affecting companies reliant on its economy.,Identifying Opportunities,: Amidst market challenge...
Avacta Showcases Promising Preclinical Results for AVA6103 and AVA7100 at 2024 EORTC-NCI-AACR Symposium
October 24, 2024 06:04 PM AEDT| By Team Kalkine MediaHighlights,Targeted Tumor Therapy,: AVA6103 and AVA7100 demonstrated strong preclinical results, focusing on tumor-specific drug delivery through FAP cleavage.,Reduced Toxicity,: Both therapies show promise in minimizing off-target effects and optimi...
Syncona’s Spur Therapeutics Reports Promising Phase I/II Data for FLT201 Gene Therapy in Gaucher Disease
October 24, 2024 01:10 AM AEDT| By Team Kalkine MediaHighlights,Positive Phase I/II Results for FLT201,: Spur Therapeutics presented encouraging data from the GALILEO-1 study, where five out of six patients treated with FLT201, a gene therapy for Gaucher disease, showed promising efficacy results.,Favo...
Scancell Holdings (AIM) Names Dr. Phil L'Huillier as CEO, Boosting Development Expertise
October 23, 2024 12:49 PM AEDT| By Team Kalkine MediaHighlights:,Dr. Phil L'Huillier appointed as CEO of Scancell (LSE), bringing extensive biotech expertise.,Current CEO, Professor Lindy Durrant, transitions to chief scientific officer and continues on the board.,Scancell is expecting significant data...
Earnings Performance of Genus (LON:GNS) Shows Promising Signs
October 22, 2024 07:29 PM AEDT| By Team Kalkine MediaHighlights:,Genus plc reported weak earnings recently, but a deeper analysis suggests the results may not fully reflect the company’s profitability potential.,The UK£48 million expense attributed to unusual items significantly impacted statutory prof...
Faron Pharmaceuticals Pursues Partnerships for Bexmarilimab Development
October 22, 2024 06:45 PM AEDT| By Team Kalkine MediaHighlights:,Faron Pharmaceuticals is seeking partnerships,to fund phase III development of its cancer drug, bexmarilimab.,Promising data from the BEXMAB trial,shows a 79% response rate in treating relapsed and refractory myelodysplastic syndrome (MDS...
Genflow Biosciences (LSE:GENF) Secures €4 Million Funding to Advance Gene Therapy for MASH
October 22, 2024 06:45 PM AEDT| By Team Kalkine MediaHighlights:,Genflow Biosciences (LSE:GENF) secures over €4 million in funding from Wallonia to advance its lead gene therapy, GF-1002.,The package includes a €1.2 million grant and a €2.8 million recoverable advance, supporting the development of MAS...
Scancell Holdings (LSE:SCLP) Appoints Dr Phil L'Huillier as New CEO
October 22, 2024 06:45 PM AEDT| By Team Kalkine MediaHighlights:,Scancell Holdings (LSE:SCLP) appoints Dr Phil L'Huillier as CEO, effective November 18.,Dr L'Huillier brings 30 years of experience in cancer immunotherapy and pharmaceutical development.,Professor Lindy Durrant will transition to focus s...
Genflow is Awarded Non-Dilutive Financial Support
October 22, 2024 06:12 PM AEDT| By Team Kalkine MediaHighlights:,Genflow Biosciences secures over €4 million in non-dilutive financial support from the Wallonia region for GF-1002 development.,The funding will facilitate the advancement of GF-1002, a gene therapy aimed at treating Metabolic Associated...
AI on the Rise: A Look at Top AI Companies and Their Stocks